XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Preferred Stock
Series D Convertible Preferred Stock
Common Stock
Common Stock
Series D Convertible Preferred Stock
Additional Paid-In Capital
Additional Paid-In Capital
Series D Convertible Preferred Stock
Additional Paid-In Capital
Series E Convertible Preferred Stock
Service Receivable
Accumulated Other Comprehensive Loss
Accumulated Deficit
Accumulated Deficit
Series D Convertible Preferred Stock
Accumulated Deficit
Series E Convertible Preferred Stock
Balance, beginning (in shares) at Dec. 31, 2019   61   8,594                  
Balance, beginning at Dec. 31, 2019 $ 7,310 $ 0   $ 8   $ 217,172     $ (972) $ 0 $ (208,898)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 177         177              
Issuance of common stock upon exercise of warrants (in shares)       1,610                  
Issuance of common stock upon exercise of warrants 1,456         1,456              
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 293               293        
Net loss (4,089)                   (4,089)    
Sale of common stock and warrants (in shares)       800                  
Sale of common stock and warrants 1,000         1,000              
Issuance of common stock upon vesting of restricted stock units (in shares)       7                  
Balance, ending (in shares) at Mar. 31, 2020   61   11,011                  
Balance, ending at Mar. 31, 2020 6,141 $ 0   $ 8   219,805     (679) 0 (212,993)    
Balance, beginning (in shares) at Dec. 31, 2019   61   8,594                  
Balance, beginning at Dec. 31, 2019 7,310 $ 0   $ 8   217,172     (972) 0 (208,898)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (8,213)                        
Balance, ending (in shares) at Jun. 30, 2020   927   21,325                  
Balance, ending at Jun. 30, 2020 24,382 $ 1   $ 9   247,528     (2,766) 0 (220,390)    
Balance, beginning (in shares) at Mar. 31, 2020   61   11,011                  
Balance, beginning at Mar. 31, 2020 6,141 $ 0   $ 8   219,805     (679) 0 (212,993)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 282         282              
Issuance of common stock upon exercise of warrants (in shares)       3,473                  
Issuance of common stock upon exercise of warrants 4,605         4,605              
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 213               213        
Net loss (4,124)                   (4,124)    
Issuance of common stock upon vesting of restricted stock units (in shares)       2                  
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares)   155   603                  
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (8)         2,292     (2,300)        
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares)     (155)   1,547                
Deemed dividend             $ 602 $ 2,665       $ (602) $ (2,665)
Sale of stock, number of shares issued (in shares) [1]   866   4,689                  
Proceeds from sale of stock [1] 17,279 $ 1   $ 1   17,277              
Balance, ending (in shares) at Jun. 30, 2020   927   21,325                  
Balance, ending at Jun. 30, 2020 24,382 $ 1   $ 9   247,528     (2,766) 0 (220,390)    
Balance, beginning (in shares) at Dec. 31, 2020   716   36,781                  
Balance, beginning at Dec. 31, 2020 128,158 $ 1   $ 4   361,819     (2,171) 0 (231,495)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 268         268              
Issuance of common stock upon exercise of warrants (in shares)       771                  
Issuance of common stock upon exercise of warrants 1,263         1,263              
Other comprehensive loss (67)                 (67)      
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 380               380        
Net loss (5,179)                   (5,179)    
Balance, ending (in shares) at Mar. 31, 2021   716   37,552                  
Balance, ending at Mar. 31, 2021 124,817 $ 1   $ 4   363,350     (1,791) (67) (236,680)    
Balance, beginning (in shares) at Dec. 31, 2020   716   36,781                  
Balance, beginning at Dec. 31, 2020 128,158 $ 1   $ 4   361,819     (2,171) 0 (231,495)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (11,936)                        
Balance, ending (in shares) at Jun. 30, 2021   716   39,552                  
Balance, ending at Jun. 30, 2021 138,918 $ 1   $ 4   383,611     (1,245) (10) (243,443)    
Balance, beginning (in shares) at Mar. 31, 2021   716   37,552                  
Balance, beginning at Mar. 31, 2021 124,817 $ 1   $ 4   363,350     (1,791) (67) (236,680)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 1,036         1,036              
Other comprehensive loss 57                 57      
Preferred stock dividend (6)                   (6)    
Release of clinical trial funding commitment 546               546        
Net loss (6,757)                   (6,757)    
Sale of common stock, net of expenses (in shares) [2]       2,000                  
Sale of common stock, net of expenses [2] 19,225         19,225              
Balance, ending (in shares) at Jun. 30, 2021   716   39,552                  
Balance, ending at Jun. 30, 2021 $ 138,918 $ 1   $ 4   $ 383,611     $ (1,245) $ (10) $ (243,443)    
[1] Net of expenses of $0.6 million, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $0.4 million.
[2] Net of expenses of $0.8 million.